Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL ... treated with anti-CD20 antibody rituximab ...

However, as the addition of rituximab to CHOP (R-CHOP) improved the outcome of all subgroups of patients with CD20 + DLBCL, a confirmation of the prognostic effect of the cell of origin in DLBCL ...

Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural ...

Columvi's design involves a 2:1 structural format, targeting CD3 on T cells and CD20 on B cells. The company continues to explore Columvi as both a single agent and with other medicines for the ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

CD20 is a CD marker—a molecule on the cell surface that can be used to identify and type a particular cell in the body. CD20 is found on the surface of B cells (a type of immune system cell).

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

In preclinical models, ARV-393 increased CD20 expression ... with relapsed/refractory non-Hodgkin lymphoma, including DLBCL (NCT06393738). Additional detail on the ARV-393 data presentation ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...